MYC and plasma cell myeloma: Nonetheless, in further support of a role for the ISR-GCN2 pathway in myeloma survival, GCN2iB-sensitive HMCLs, as well as Vκ*MYC tumours (Vκ12598), undergo apoptosis upon treatment with GCN2iB (Fig. 6e, f, and Supplementary Fig. 8c, d).